Literature DB >> 28975447

Tumor necrosis factor alpha-stimulated gene-6 (TSG-6) inhibits the inflammatory response by inhibiting the activation of P38 and JNK signaling pathway and decreases the restenosis of vein grafts in rats.

Chengxin Zhang1,2, Biao Zhang1, Huiping Wang2, Qianshan Tao2, Shenglin Ge3, Zhimin Zhai4.   

Abstract

This study aims to explore the effects of tumor necrosis factor alpha-stimulated gene-6 (TSG-6) on vascular inflammatory response and vascular injury in grafted vein wall of rats and its possible mechanism. Vascular grafting model was established by modified cuff. The effect of TSG-6 on the inflammatory response and vascular injury of vein graft was investigated. The activation of mast cells and macrophages after LPS stimulation was observed by lentivirus-mediated upregulation or downregulation of TSG-6 expression. The results showed that rhTSG-6 treatment could significantly inhibit the proliferation of venous bridge, decrease macrophage infiltration and smooth muscle cell proliferation. The expression levels of TNF-α and IL-1 in treated group were significantly lower than that of untreated group (P < 0.05), while the expression of IL-10 in treated group were significantly higher than that of untreated group (P < 0.05). The expression levels of P38, p-P38, JNK and p-JNK in venous bridge of rats were significantly lower than those of untreated rats (P < 0.05), while there was no significant difference in the expression level of ERK and p-ERK (P > 0.05). TSG-6 could inhibit the proliferation of mast cells and macrophages and the release of inflammatory cytokines by down regulating the expression levels of P38, p-P38, JNK and p-JNK. TSG-6 can inhibit the inflammatory response of transplanted vein grafts in rats and reduce vascular injury by downregulation of P38 and JNK signaling pathway.

Entities:  

Keywords:  Grafted vein; Proinflammatory response; Tumor necrosis factor alpha-stimulated gene-6 (TSG-6); Venous bridge

Mesh:

Substances:

Year:  2017        PMID: 28975447     DOI: 10.1007/s00380-017-1059-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  34 in total

Review 1.  Inhibition of neointimal formation and hyperplasia in vein grafts by external stent/sheath.

Authors:  Mital Desai; Jalaledin Mirzay-Razzaz; Dirk von Delft; Sandip Sarkar; George Hamilton; Alexander M Seifalian
Journal:  Vasc Med       Date:  2010-05-28       Impact factor: 3.239

2.  Inflammation Effects on Stent Restenosis.

Authors:  Selcuk Kucukseymen
Journal:  Angiology       Date:  2017-03-30       Impact factor: 3.619

3.  PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design.

Authors:  Erik W Holy; Philipp Jakob; Thomas Eickner; Giovanni G Camici; Jürg H Beer; Alexander Akhmedov; Katrin Sternberg; Klaus-Peter Schmitz; Thomas F Lüscher; Felix C Tanner
Journal:  Eur Heart J       Date:  2013-12-11       Impact factor: 29.983

Review 4.  Mast cells in allergic and inflammatory diseases.

Authors:  Nikolaos Sismanopoulos; Danae-Anastasia Delivanis; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Anastasia Therianou; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis.

Authors:  T Bárdos; R V Kamath; K Mikecz; T T Glant
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Administration of TSG-6 improves memory after traumatic brain injury in mice.

Authors:  Jun Watanabe; Ashok K Shetty; Bharathi Hattiangady; Dong-Ki Kim; Jessica E Foraker; Hidetaka Nishida; Darwin J Prockop
Journal:  Neurobiol Dis       Date:  2013-07-11       Impact factor: 5.996

7.  Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease.

Authors:  Margreet R de Vries; Anouk Wezel; Abbey Schepers; Peter J van Santbrink; Trent M Woodruff; Hans W M Niessen; Jaap F Hamming; Johan Kuiper; Ilze Bot; Paul H A Quax
Journal:  Cardiovasc Res       Date:  2012-10-14       Impact factor: 10.787

8.  Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs.

Authors:  Andrea M Foskett; Nikolay Bazhanov; Xinyu Ti; April Tiblow; Thomas J Bartosh; Darwin J Prockop
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-15       Impact factor: 5.464

9.  The selective mGluR5 agonist CHPG attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells.

Authors:  Jun-Ling Qiu; Wen-Li Zhu; Yu-Jie Lu; Zheng-Fa Bai; Zhi-Gang Liu; Pei Zhao; Chao Sun; Ya-Bin Zhang; Hua Li; Wei Liu
Journal:  Neurochem Int       Date:  2015-05-04       Impact factor: 3.921

10.  Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury.

Authors:  Sihyung Wang; Ji-Seon Lee; Jeongeun Hyun; Jieun Kim; Seung U Kim; Hyuk-Jin Cha; Youngmi Jung
Journal:  Stem Cell Res Ther       Date:  2015-03-11       Impact factor: 6.832

View more
  3 in total

Review 1.  Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist).

Authors:  Tommaso Gori
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

Review 2.  Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis.

Authors:  Rena Watanabe; Yuki Sato; Nana Ozawa; Yui Takahashi; Shinji Koba; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-02-05       Impact factor: 5.923

3.  Identification of potential crucial genes and pathways associated with vein graft restenosis based on gene expression analysis in experimental rabbits.

Authors:  Qiang Liu; Xiujie Yin; Zhuoqi Liu; Qun Wang; Mingzhu Li; Li Wan; Liqiao Liu; Xiang Zhong
Journal:  PeerJ       Date:  2018-05-16       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.